Entrada Therapeutics
TRDA
TRDA
111 hedge funds and large institutions have $290M invested in Entrada Therapeutics in 2025 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 42 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
1.47% less ownership
Funds ownership: 86.52% → 85.06% (-1.5%)
33% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 42
48% less capital invested
Capital invested by funds: $560M → $290M (-$270M)
Holders
111
Holding in Top 10
4
Calls
$124K
Puts
$21K
Top Buyers
| 1 | +$1.47M | |
| 2 | +$1.01M | |
| 3 | +$996K | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$395K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$226K |
Top Sellers
| 1 | -$1.74M | |
| 2 | -$1.5M | |
| 3 | -$1.45M | |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$892K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$670K |
